2型糖尿病患者感染新冠病毒后肝脏脂质含量的变化
Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes.
作者信息
Kupriyanova Yuliya, Yurchenko Iryna, Bobrov Pavel, Bartels Frederik, Wierichs Stefan, Jonuscheit Marc, Korzekwa Benedict, Prystupa Katsiaryna, Schön Martin, Mendez Dania, Trenkamp Sandra, Burkart Volker, Wagner Robert, Schrauwen-Hinderling Vera, Roden Michael
机构信息
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
German Center for Diabetes Research (DZD), Partner Düsseldorf, Neuherberg, Germany.
出版信息
BMJ Open Diabetes Res Care. 2025 Feb 18;13(1):e004727. doi: 10.1136/bmjdrc-2024-004727.
INTRODUCTION
The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes.
RESEARCH DESIGN AND METHODS
Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58±12 years, body mass index 30.9±5.2 kg/m) were examined before (baseline) and 1 year (12±2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61±6 years, 30.0±4.6 kg/m).
RESULTS
COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed.
CONCLUSIONS
History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.
TRIAL REGISTRATION NUMBER
NCT01055093.
引言
本研究旨在评估2型糖尿病患者感染新型冠状病毒肺炎（COVID-19）后对肝脏脂质（HL）含量、纤维化风险和肥胖的影响。
研究设计与方法
选取有轻度COVID-19病史的2型糖尿病患者（n = 15，年龄58±12岁，体重指数30.9±5.2kg/m²），在从COVID-19康复前（基线）和康复后1年（12±2个月）（随访）进行检查。代谢风险变化的调查包括临床检查、空腹采血和基于磁共振成像（MR）的测量。在一组未在同一时间段感染COVID-19的参与者（n = 14，61±6岁，30.0±4.6kg/m²）中，用各自参数的时间进程对潜在变化进行校正。
结果
以质子密度脂肪分数（HL-PDFF）衡量，COVID-19导致HL含量相对增加56%（95%置信区间18%，106%；p = 0.04），校正了未感染COVID-19时的时间进程。未观察到肝硬度、肝体积、肌内脂质、全身、皮下和内脏脂肪组织体积以及胰岛素抵抗和β细胞功能的稳态模型评估有变化。
结论
2型糖尿病患者感染COVID-19后，在感染康复1年后与较高的HL-PDFF相关。
试验注册号
NCT01055093。
Zotero 插件